BPE — Marked
Marked BPE is the highest level of background parenchymal enhancement in the BI-RADS v2025 MRI lexicon, representing extensive, intense enhancement throughout the fibroglandular tissue (FGT) on early post-contrast imaging.
Definition
Marked BPE is defined as diffuse, intense enhancement involving the vast majority of fibroglandular tissue, assessed on the first post-contrast subtraction series (typically 60–120 seconds after gadolinium injection). In BI-RADS v2025, BPE is graded on a four-tier scale: minimal (includes no enhancement), mild, moderate, and marked. The assessment should be made on early-phase images because FGT enhancement increases over time and delayed-phase assessment inflates the perceived BPE level.
Board Pearl
BPE level must be assessed on the first post-contrast subtraction series — NOT on delayed images. Evaluating BPE on delayed sequences overestimates the level and may lead to unnecessary short-interval follow-up recommendations.
Imaging Appearance
Post-Contrast T1W / Subtraction
- Intense, widespread enhancement of nearly all visible fibroglandular tissue
- On MIP (maximum intensity projection) images, the entire breast parenchyma appears “lit up,” making it difficult to distinguish focal enhancing lesions from background
- Enhancement is typically bilateral and relatively symmetric in premenopausal patients during the luteal phase (days 7–14 of the menstrual cycle)
T2-Weighted
- FGT appears intermediate to high signal; marked BPE does not alter T2 characteristics
- T2 signal can help differentiate true lesions (e.g., T2-hyperintense cysts or fibroadenomas) from enhancing background tissue
DWI (Diffusion-Weighted Imaging)
- Marked BPE can produce diffusion restriction artifacts in normal FGT, complicating ADC map interpretation
- True restricted diffusion from malignancy is typically more focal and lower ADC (<1.0–1.2 × 10⁻³ mm²/s) than background FGT signal
Symmetry Assessment
BI-RADS v2025 requires reporting BPE symmetry as a separate descriptor alongside level:
- Symmetric — bilateral, roughly equal enhancement intensity
- Asymmetric — unilateral or markedly unequal enhancement between breasts
Asymmetric marked BPE is clinically significant and should not be dismissed as physiologic without explanation. Known causes of asymmetric BPE include prior surgery, radiation therapy, or hormonal asymmetry. When no explanation exists, the more enhancing side warrants further evaluation.
Board Pearl
Marked BPE is NOT a finding — it is a tissue descriptor. It should never be assigned a BI-RADS assessment category. However, unexplained asymmetric marked BPE may warrant short-interval follow-up or targeted evaluation of the more enhancing breast.
Factors Affecting BPE Level
| Factor | Effect on BPE |
|---|---|
| Menstrual cycle (luteal phase) | ↑ BPE — schedule MRI days 7–14 (follicular phase) |
| Premenopausal status | ↑ BPE compared to postmenopausal |
| Hormone replacement therapy (HRT) | ↑ BPE — consider discontinuation 4–6 weeks prior |
| Tamoxifen | ↓ BPE (anti-estrogenic effect on breast tissue) |
| Aromatase inhibitors | ↓ BPE |
| Oophorectomy / menopause | ↓ BPE |
| Lactation | ↑↑ BPE — often marked and diffuse |
| Prior radiation | ↓ BPE in irradiated breast |
Board Pearl
To minimize BPE and optimize lesion detection, schedule breast MRI during days 7–14 of the menstrual cycle (mid-follicular phase). Premenopausal patients imaged in the luteal phase frequently demonstrate marked BPE that resolves on repeat imaging at optimal timing.
Clinical Significance
- Reduced sensitivity: Marked BPE is the single greatest limitation to lesion detection on breast MRI. Enhancing cancers can be completely obscured by intensely enhancing background tissue.
- Increased callbacks: More likely to generate false-positive findings and BI-RADS 3 assessments due to difficulty distinguishing true lesions from background.
- Screening impact: In high-risk screening, marked BPE may warrant repeat imaging at optimal cycle timing rather than a BI-RADS 3 for equivocal enhancement.
- Monitoring response: BPE reduction during neoadjuvant chemotherapy is expected; persistent marked BPE may complicate tumor response assessment.
Differential Diagnosis — Mimics of Marked BPE
| Entity | Distinguishing Features |
|---|---|
| Diffuse NME (Non-Mass Enhancement — Diffuse Distribution) | True NME has a specific NME Internal Enhancement Pattern (clumped, clustered ring); BPE follows FGT distribution |
| Inflammatory breast cancer | Unilateral skin thickening, trabecular thickening, axillary lymphadenopathy; clinical signs (peau d’orange, erythema) |
| Diffuse DCIS | Often segmental or regional; may show segmental clumped NME rather than smooth BPE |
| Lactational change | Clinical history; bilateral marked BPE with skin thickening is expected |
Pitfalls
- Overcalling BPE as NME: Marked BPE follows the distribution of FGT and enhances smoothly. Non-Mass Enhancement has a distinct distribution and internal enhancement pattern — look for clumped or clustered ring enhancement.
- Delayed-phase assessment: Evaluating BPE on delayed images inflates the perceived level and may cause unnecessary recommendations.
- Ignoring asymmetry: Symmetric marked BPE is typically physiologic. Asymmetric marked BPE requires explanation — do not default to “hormonal.”
- Failing to recommend re-imaging: When marked BPE obscures the study, consider recommending repeat MRI at optimal menstrual cycle timing rather than issuing BI-RADS 0 or 3.
Edition Conflict
The 5th edition did not include minimal as a BPE level — it used only mild, moderate, and marked. BI-RADS v2025 added minimal (includes no enhancement) as the lowest tier. This means some cases previously classified as “mild” BPE may now be reclassified as “minimal.” The threshold for marked BPE itself is unchanged.
Management Implications
- Marked BPE alone does not change the BI-RADS assessment category
- If marked BPE limits evaluation, the report should state this explicitly as a limitation
- Consider recommending repeat MRI at optimal timing (follicular phase) if BPE obscures interpretation
- In neoadjuvant chemotherapy monitoring, document baseline BPE level — marked BPE at baseline that persists may limit tumor response assessment
- Computer-aided detection (CAD) and AI tools may have reduced performance in the setting of marked BPE